Clinical Trial

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Name: 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors — clinical trial record (NCT07404332)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-29

Trial Details

NCT Number	NCT07404332
Lead Sponsor	Mohammed Milhem
Conditions	Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
Enrollment	35 participants
Start Date	2026-02-11
Primary Completion	2028-02-28 (estimated)
Study Completion	2031-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-05-28